Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02231515
Recruitment Status : Unknown
Verified September 2014 by Dr. Kaweh Mansouri, University Hospital, Geneva.
Recruitment status was:  Recruiting
First Posted : September 4, 2014
Last Update Posted : September 4, 2014
Sponsor:
Information provided by (Responsible Party):
Dr. Kaweh Mansouri, University Hospital, Geneva

Brief Summary:
A prospective, randomized, controlled study to assess efficacy, safety, and tolerability of selective laser trabeculoplasty vs. pattern laser trabeculoplasty in patients with open-angle glaucoma.

Condition or disease Intervention/treatment Phase
Glaucoma and Ocular Hypertension Device: Selective laser trabeculoplasty (SLT) Device: Pattern laser trabeculoplasty (PLT) Phase 4

Detailed Description:

This is a prospective, randomised, controlled study. Patients will be selected for this study who require bilateral laser trabeculoplasty for IOP control. Eyes will undergo a medication wash-out 4 weeks prior to the baseline study session (S1). There will be a security visit at 2 weeks to make sure that the IOPs remain within a safe range. Following S1 both study eyes will receive laser treatment, as assigned by randomization, within a period of 2 weeks. Eyes will be randomized to receive the SLT (SLT eye) or PLT (PLT eye) treatment. Both laser procedures will be performed in one session (for 360° of the angle), if patients tolerate it. Otherwise, they will be split into two sessions (each treating 180° of the angle) to be performed within 1 week of each other. The same pre- and post-laser procedures will be applied on both eyes.

After having signed and dated the patient informed consent form, patients will undergo an initial ophthalmic examination. The CLS will be placed on both eyes for a baseline 24-hour IOP pattern recording session (S1), within 2 weeks preceding the laser treatment. Patients will remain ambulatory and will be encouraged to follow a schedule as close to his/her usual lifestyle as possible. At hour 24, patients will return to the clinic, the device will be removed and a final ophthalmic examination will be conducted. Patient diary will be collected and concomitant medication will be reported.

Following S1 both study eyes will receive either SLT or PLT laser treatment, as assigned by randomization (1:1), within a period of 2 weeks. The same pre- and post-laser procedures will be applied on both eyes.

At S2 (1 month after laser treatment) patients will be randomized to 24-hour CLS recording on either the SLT or on the PLT eye (1:1). The same ophthalmic examinations as during S1 will be conducted and patient diary collected.

At month 3 patients will be followed up with a slit lamp examination and IOP measurement. At months 6 and 12, patients will be seen for a complete ophthalmic examination including visual field exam (Octopus, Switzerland), optic nerve and retinal nerve fiber layer evaluation (Spectralis OCT, Germany). The overall study duration for the patient is limited to up to 14 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma
Study Start Date : April 2014
Estimated Primary Completion Date : April 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: Pattern laser trabeculoplasty (PLT)
Pattern laser trabeculoplasty
Device: Pattern laser trabeculoplasty (PLT)
Pattern laser trabeculoplasty (PLT)

Active Comparator: Selective laser trabeculoplasty (SLT)
Selective laser trabeculoplasty (SLT)
Device: Selective laser trabeculoplasty (SLT)
Selective laser trabeculoplasty




Primary Outcome Measures :
  1. • Change in IOP from baseline to 1 month post-surgery as measured by tonometry [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. o Complete success: Reduction of at least 20% in IOP without medication [ Time Frame: 1 month ]
  2. o Qualified success: Reduction of at least 20% in IOP with IOP-lowering medication [ Time Frame: 1 Month ]

Other Outcome Measures:
  1. • CLS derived parameters including: o Wake-to-Sleep slopes, as measured by the linear change in IOP from before going to bed to after [ Time Frame: 3 and 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of open angle glaucoma (OAG) including pseudo-exfoliative and pigmentary glaucoma
  • Patients requiring bilateral laser trabeculoplasty for IOP control
  • Structural glaucomatous damage and/or documented glaucomatous VF damage (in the previous 12 months with mean defect (MD) > 2.5 dB
  • No or stable anti-glaucomatous drug therapy since at least 3 months. Able to undergo medication washout for 4 weeks prior to baseline 24-h IOP monitoring session.
  • Aged ≥18 years, of either sex
  • Not more than 6 diopters spherical equivalent on the study eye
  • Have given written informed consent, prior to any investigational procedures

Exclusion Criteria:

  • Refractory glaucoma
  • Patients having undergone ocular laser procedures (SLT, LPI) or intraocular surgery for the treatment of glaucoma.
  • Corneal or conjunctival abnormality precluding contact lens adaptation
  • Severe dry eye syndrome
  • Patients with allergy to corneal anesthetic
  • Patients with contraindications for silicone contact lens wear
  • Patients not able to understand the character and individual consequences of the investigation
  • Participation in other clinical research within the last 4 weeks
  • Any other contra-indication listed in the CLS (SENSIMED Triggerfish) user manual

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02231515


Contacts
Layout table for location contacts
Contact: Kaweh Mansouri +41 79 553 38 64 kaweh.mansouri@hcuge.ch

Locations
Layout table for location information
Switzerland
Hôpitaux Universitaires de Genève, Ophtalmology Department Recruiting
Geneva, Switzerland
Principal Investigator: Kaweh Mansouri         
Sponsors and Collaborators
University Hospital, Geneva
Investigators
Layout table for investigator information
Principal Investigator: Kaweh Mansouri Ophtalmology department - Hôpitaux Universitaires de Genève
Layout table for additonal information
Responsible Party: Dr. Kaweh Mansouri, MD, University Hospital, Geneva
ClinicalTrials.gov Identifier: NCT02231515    
Other Study ID Numbers: 1219
First Posted: September 4, 2014    Key Record Dates
Last Update Posted: September 4, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Ocular Hypertension
Eye Diseases